Clinical Trial Update: Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial [Phase 2]

View source ↗

Summary

Phase 2 study evaluating the combination of selumetinib with olaparib, or selumetinib alone, for RAS pathway-mutant recurrent or persistent ovarian and endometr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Cancer
• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• Koselugo (selumetinib)
• Lynparza (olaparib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Endometrial Carcinoma, Recurrent Fallopian Tube Carcinoma | Phase 2 | Status: RECRUITING